title: [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
abstract: Via their central point of attack on the nuclear PPAR gamma receptors, thiazolidinediones improve insulin sensitivity and thus bring lower blood sugar and insulin levels. Depending on the group of patients investigated, they reduce the HbA1c by 0.7% to 1.5%. Rosiglitazone and pioglitazone will soon be available on the European market. In contrast to troglitazone they show no signs of any hepatotoxic effect in the studies performed to date. Common to the class of insulin sensitizers is their effect in promoting the differentiation of subcutaneous adipocytes, leading to subsequent weight increase and the development of edema.
authors.affiliation: Univ.-Klinik für Innere Medizin III, Wien. bernhard.ludvik@akh-wien.ac.at
authors.forename: B
authors.initials: B
authors.lastname: Ludvik
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007333:Insulin Resistance; D000077205:Pioglitazone; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D045162:Thiazolidinediones
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone